The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD

The Lung Health Study

Robert A Wise, Richard E. Kanner, Paula Lindgren, John E. Connett, Murray D. Altose, Paul L. Enright, Donald P. Tashkin

Research output: Contribution to journalArticle

Abstract

Background: The Lung Health Study (LHS), a 5-year, randomized, prospective clinical trial, studied the effects of smoking intervention and therapy with inhaled anticholinergic bronchodilators on FEV1 in participants who were 35 to 60 years of age and had mild COPD. Participants were randomized into the following three groups: usual care; smoking cessation plus inhaled ipratropium bromide; and smoking cessation plus placebo inhaler. This report evaluates the effects of these interventions, demographic characteristics, smoking status, and FEV1 changes on airway responsiveness (AR). Methods and results: Of 5,887 participants, 4,201 underwent methacholine challenge testing both at study entry and study completion. All groups increased AR during the 5-year period. The increase in AR was greatest in continuing smokers and was associated with a greater FEV1 decline. An intent-to-treat analysis indicated no significant differences in AR changes among the three groups. Conclusions: Changes in AR over a 5-year period in the LHS were primarily related to changes in the FEV1. The greater the decline in FEV1, the greater the increase in AR. Smoking cessation had a small additional benefit in AR beyond its favorable effects on FEV 1 changes.

Original languageEnglish (US)
Pages (from-to)449-458
Number of pages10
JournalChest
Volume124
Issue number2
DOIs
StatePublished - Aug 1 2003

Fingerprint

Bronchodilator Agents
Smoking Cessation
Chronic Obstructive Pulmonary Disease
Smoking
Lung
Health
Ipratropium
Methacholine Chloride
Nebulizers and Vaporizers
Cholinergic Antagonists
Randomized Controlled Trials
Placebos
Demography
Therapeutics

Keywords

  • Airway hyperresponsiveness
  • Airways reactivity
  • COPD
  • Ipratropium
  • Methacholine bronchoprovocation challenge
  • Smoking cessation

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Wise, R. A., Kanner, R. E., Lindgren, P., Connett, J. E., Altose, M. D., Enright, P. L., & Tashkin, D. P. (2003). The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD: The Lung Health Study. Chest, 124(2), 449-458. https://doi.org/10.1378/chest.124.2.449

The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD : The Lung Health Study. / Wise, Robert A; Kanner, Richard E.; Lindgren, Paula; Connett, John E.; Altose, Murray D.; Enright, Paul L.; Tashkin, Donald P.

In: Chest, Vol. 124, No. 2, 01.08.2003, p. 449-458.

Research output: Contribution to journalArticle

Wise, RA, Kanner, RE, Lindgren, P, Connett, JE, Altose, MD, Enright, PL & Tashkin, DP 2003, 'The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD: The Lung Health Study', Chest, vol. 124, no. 2, pp. 449-458. https://doi.org/10.1378/chest.124.2.449
Wise, Robert A ; Kanner, Richard E. ; Lindgren, Paula ; Connett, John E. ; Altose, Murray D. ; Enright, Paul L. ; Tashkin, Donald P. / The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD : The Lung Health Study. In: Chest. 2003 ; Vol. 124, No. 2. pp. 449-458.
@article{775700a16f484c8aa707b2916a0d43ea,
title = "The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD: The Lung Health Study",
abstract = "Background: The Lung Health Study (LHS), a 5-year, randomized, prospective clinical trial, studied the effects of smoking intervention and therapy with inhaled anticholinergic bronchodilators on FEV1 in participants who were 35 to 60 years of age and had mild COPD. Participants were randomized into the following three groups: usual care; smoking cessation plus inhaled ipratropium bromide; and smoking cessation plus placebo inhaler. This report evaluates the effects of these interventions, demographic characteristics, smoking status, and FEV1 changes on airway responsiveness (AR). Methods and results: Of 5,887 participants, 4,201 underwent methacholine challenge testing both at study entry and study completion. All groups increased AR during the 5-year period. The increase in AR was greatest in continuing smokers and was associated with a greater FEV1 decline. An intent-to-treat analysis indicated no significant differences in AR changes among the three groups. Conclusions: Changes in AR over a 5-year period in the LHS were primarily related to changes in the FEV1. The greater the decline in FEV1, the greater the increase in AR. Smoking cessation had a small additional benefit in AR beyond its favorable effects on FEV 1 changes.",
keywords = "Airway hyperresponsiveness, Airways reactivity, COPD, Ipratropium, Methacholine bronchoprovocation challenge, Smoking cessation",
author = "Wise, {Robert A} and Kanner, {Richard E.} and Paula Lindgren and Connett, {John E.} and Altose, {Murray D.} and Enright, {Paul L.} and Tashkin, {Donald P.}",
year = "2003",
month = "8",
day = "1",
doi = "10.1378/chest.124.2.449",
language = "English (US)",
volume = "124",
pages = "449--458",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "2",

}

TY - JOUR

T1 - The effect of smoking intervention and an inhaled bronchodilator on airways reactivity in COPD

T2 - The Lung Health Study

AU - Wise, Robert A

AU - Kanner, Richard E.

AU - Lindgren, Paula

AU - Connett, John E.

AU - Altose, Murray D.

AU - Enright, Paul L.

AU - Tashkin, Donald P.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Background: The Lung Health Study (LHS), a 5-year, randomized, prospective clinical trial, studied the effects of smoking intervention and therapy with inhaled anticholinergic bronchodilators on FEV1 in participants who were 35 to 60 years of age and had mild COPD. Participants were randomized into the following three groups: usual care; smoking cessation plus inhaled ipratropium bromide; and smoking cessation plus placebo inhaler. This report evaluates the effects of these interventions, demographic characteristics, smoking status, and FEV1 changes on airway responsiveness (AR). Methods and results: Of 5,887 participants, 4,201 underwent methacholine challenge testing both at study entry and study completion. All groups increased AR during the 5-year period. The increase in AR was greatest in continuing smokers and was associated with a greater FEV1 decline. An intent-to-treat analysis indicated no significant differences in AR changes among the three groups. Conclusions: Changes in AR over a 5-year period in the LHS were primarily related to changes in the FEV1. The greater the decline in FEV1, the greater the increase in AR. Smoking cessation had a small additional benefit in AR beyond its favorable effects on FEV 1 changes.

AB - Background: The Lung Health Study (LHS), a 5-year, randomized, prospective clinical trial, studied the effects of smoking intervention and therapy with inhaled anticholinergic bronchodilators on FEV1 in participants who were 35 to 60 years of age and had mild COPD. Participants were randomized into the following three groups: usual care; smoking cessation plus inhaled ipratropium bromide; and smoking cessation plus placebo inhaler. This report evaluates the effects of these interventions, demographic characteristics, smoking status, and FEV1 changes on airway responsiveness (AR). Methods and results: Of 5,887 participants, 4,201 underwent methacholine challenge testing both at study entry and study completion. All groups increased AR during the 5-year period. The increase in AR was greatest in continuing smokers and was associated with a greater FEV1 decline. An intent-to-treat analysis indicated no significant differences in AR changes among the three groups. Conclusions: Changes in AR over a 5-year period in the LHS were primarily related to changes in the FEV1. The greater the decline in FEV1, the greater the increase in AR. Smoking cessation had a small additional benefit in AR beyond its favorable effects on FEV 1 changes.

KW - Airway hyperresponsiveness

KW - Airways reactivity

KW - COPD

KW - Ipratropium

KW - Methacholine bronchoprovocation challenge

KW - Smoking cessation

UR - http://www.scopus.com/inward/record.url?scp=0042231984&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042231984&partnerID=8YFLogxK

U2 - 10.1378/chest.124.2.449

DO - 10.1378/chest.124.2.449

M3 - Article

VL - 124

SP - 449

EP - 458

JO - Chest

JF - Chest

SN - 0012-3692

IS - 2

ER -